Who We Are
Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of resistant and difficult to treat infections. MBN-101, our first therapeutic candidate, has demonstrated in vitro broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs” identified by the US Centers for Disease Control and Prevention (CDC). In addition, MBN-101 also has demonstrated the ability to prevent and eradicate microbial biofilms. The dual action of antimicrobial / anti-biofilm activity has the potential to become a first-in-class, best-in-class clinical approach to treating serious and life-threatening infections.